Literature DB >> 14584662

Microvessel density as a prognostic factor in preinvasive and invasive cervical lesions.

S Ozalp1, O T Yalcin, U Oner, H M Tanir, M Acikalin, I Sarac.   

Abstract

OBJECTIVE: To assess angiogenesis in preinvasive and invasive cervical lesions and its prognostic value in squamous cell carcinoma (SCC).
METHODS: Twenty-seven cervical intraepithelial lesions (CIN I, II and III), 27 Stage Ib-IIa SCC and 12 normal cervical epithelium were included in the study. Clinico-pathological prognostic factors were re-evaluated from the patients' files and previous tissue sections. Microvessel density (MVD), a marker for angiogenesis, was assessed from new tissue blocks by an immunohistochemical staining method. Statistical tests included Kruskall-Wallis analysis, the Mann-Whitney U-test, Fisher's exact t-test to analyse the categorical data and Cox regression and Kaplan-Meier survival analyses to define the effect of prognosticators on survival.
RESULTS: CIN II and III lesions had significantly higher MVD counts than normal epithelium and CIN I lesions, both of which had similar MVD count. Compared to preinvasive lesions invasive SCC had significantly higher MVD counts. Among SCC cases, only pelvic lymph node involvement appeared to be independent risk factor on unvariate analysis. However, MVD, as a cut-off value of 21 determined by ROC analysis, was found to be an independent prognosticator in early stage SCC cases by multivariate analysis.
CONCLUSION: Despite the small number of enrolled cases, the results of this study suggest that angiogenesis involved in the development and progression of cervical neoplasms and MVD might be used as a prognostic factor.

Entities:  

Mesh:

Year:  2003        PMID: 14584662

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  5 in total

1.  Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.

Authors:  Colleen L Doçi; Tanmayi P Mankame; Alexander Langerman; Kelly R Ostler; Rajani Kanteti; Timothy Best; Kenan Onel; Lucy A Godley; Ravi Salgia; Mark W Lingen
Journal:  Int J Gynecol Pathol       Date:  2012-01       Impact factor: 2.762

2.  Correlation of Twist upregulation and senescence bypass during the progression and metastasis of cervical cancer.

Authors:  Tian Wang; Yan Li; Abidan Tuerhanjiang; Wenwen Wang; Zhangying Wu; Ming Yuan; Shixuan Wang
Journal:  Front Med       Date:  2014-01-08       Impact factor: 4.592

3.  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Authors:  Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-04-13       Impact factor: 5.482

4.  Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression.

Authors:  Juliana Passos Paschoal; Vagner Bernardo; Nathalie Henriques Silva Canedo; Osmar Damasceno Ribeiro; Adriana Caroli-Bottino; Vera Lucia Pannain
Journal:  BMC Cancer       Date:  2014-02-07       Impact factor: 4.430

5.  Diagnostic Modalities of Precancerous and Cancerous Cervical Lesions with Special Emphasis on CD31 Angiogenesis Factor as a Marker.

Authors:  Bandana Sharma; Neetu Singh; Neena Gupta; Pavika Lal; Shefali Pande; Shashi Chauhan
Journal:  Patholog Res Int       Date:  2013-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.